Spray-Dried Amorphous TMC125 Solid Dispersion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge is to enhance the bioavailability of the poorly water-soluble anti-HIV compound TMC125, which results in low bioavailability and high pill burden when administered in its crystalline form, making it difficult to compact into dosage forms like tablets or capsules due to its fluffy and low-density powder characteristics.
Innovation Solution
A process involving the spray-drying of a feed mixture containing microcrystalline cellulose and a water-soluble polymer with TMC125, which increases the dissolution speed and density of the powder, allowing for easier formulation into pharmaceutical forms with reduced pill burden.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TMC125 is administered in its crystalline form, then the dosage form can be compacted into tablets or capsules, but the bioavailability is low and pill burden is high
Solution Approach 1:
The patent changes the physical state parameter of TMC125 from crystalline to amorphous form. This parameter change improves bioavailability by increasing dissolution rate, while the amorphous material is incorporated into a spray-dried powder formulation that maintains compaction capability through the use of excipients and controlled particle morphology.
Solution Approach 2:
The patent creates a composite material system where amorphous TMC125 is dispersed in a matrix of excipients including cellulose derivatives and other pharmaceutical additives. This composite structure provides both the high bioavailability of amorphous drug and the manufacturability of a compactable powder formulation suitable for tablet or capsule production.
2Reliability
If the dose is increased to compensate for low bioavailability, then the therapeutic effect is maintained, but the pill burden increases
Solution Approach 1:
By changing the physical state from crystalline to amorphous, the dissolution rate and bioavailability are enhanced, allowing a lower dose to achieve the same therapeutic effect. This reduces the quantity of active substance needed per dosage unit, thereby reducing pill burden.
3Speed
If amorphous form is used to improve bioavailability, then dissolution speed increases, but the powder becomes fluffy and low-density making it difficult to compact
Solution Approach 1:
The amorphous TMC125 is formulated as a composite powder system containing multiple excipients including cellulose derivatives, lubricants, and flow agents. This composite structure provides the high dissolution speed of amorphous drug while the excipient matrix provides appropriate flow and compaction properties for manufacturing.
Solution Approach 2:
Excipients act as intermediaries between the amorphous TMC125 and the final dosage form. These intermediary substances bridge the gap by providing the mechanical properties needed for compaction while allowing the amorphous drug to maintain its high dissolution rate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process produces a high-density, amorphous solid dispersion of TMC125 with improved bioavailability, reducing the need for pre-compacting and minimizing the pill burden by increasing plasma levels and onset speed of the drug.
Implementation Method 1
spray-drying the feed mixture from step (a) to form a solid dispersion of the pharmaceutical agent and the polymer by introducing the feed mixture as droplets into a spray-drying chamber via an atomizing means
Data Source
AI summary
This invention relates to a process for producing a spray-dried powder comprising microcrystalline cellulose in a solid dispersion of the anti-HIV compound etravirine (TMC125) in a water-soluble polymer.